Hey JJ ... I'm still pretty optimistic, but I do enjoy your down to earth posts. I can only imagine how the trruly long term investors feel, I have only been around for 5-ish years, and feel the same in many regards. I think a big difference these days is the BTD, to go along with the safety profile. IOW they have the stodgy FDA's attention. This gets BP's attention, along with the sizable potential market.

I think a lot is riding on the FDA disposition letter, hope Don wasn't drunk when he said the June 2 FDA meeting went "very very well" ... it's dominoes now, 1) FDA disposition letter, 2) related BP partnering involvement/deal, 3) nailing the next study based on endpoint targets aligning with known powerful BoM results.

Phase 1 ROI ... partnering on the next study = pps impact of some kind, maybe enough for those of us over-invested financially and emotionally to "get out" healthy with a tidy ROI

Phase 2 ROI ... study meeting endpoints in 1-3 years, BP buy out, remaining long term players get an even more generous ROI

Still long myself, resting on past study data and hoping like heck they get it right this time with BP assistance and guidance ... with BP "greed" driving the train to ROI

Closing a partnering deal is going to be key, and the next HUGE milestone, after the FDA letter. If you have one of the SOC treatments with which apabetalone works well, you want the drug to go into differentiation/dominance mode, and you certainly want to keep it away from your competitors to PROTECT your current market position and revenues stream.

I'm choosing to ride this out with Dart, Hepa, and other internal financial supporters who have more info than me and continue to pour cash into the "opportunity" ... along with what I think I "see" the safety and data, and market value and postioning for BP.

jmho